drugset / Trial / NCT00530361

An Efficacy and Safety Study for Nesiritide in Heart Failure Patients With Reduced Kidney Function Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (CPB Pump or Heart Lung Machine)

NCT00530361 ↗

Phase 3 Withdrawn Scios, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess whether nesiritide compared to placebo when given with standard of care therapies, helps preserve kidney function in heart failure (HF) patients undergoing heart bypass graft surgery that requires the use of a cardiopulmonary bypass machine (CPB pump or heart-lung machine).

Timeline

Start
—
Primary completion
—
Completion
2009-09

Outcome

Outcome not reported

Stopped (Business): “Study was withdrawn prior to patient dosing based on a business decision.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Nesiritide Protein / enzyme biologic 0.01 ug/kg Intravenous